Furthermore, a randomized phase II trial of the combination of erlotinib, EGFR-TKI, with placebo or an R1507, another anti-IGF1R monoclonal antibody, was also performed for advanced NSCLC [34]. This evidence concerns the gene IGF1R and non-small cell lung carcinoma.